DKDam Kim

Dam Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dam Kim has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reliability and Quality of Korean YouTube Videos for Education Regarding Gout

    by Bon San Koo, Dam Kim, Jae-Bum Jun

    Koo BS, et al. J Korean Med Sci. 2021 Oct;36(45):e303. https://doi.org/10.3346/jkms.2021.36.e303


  • Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values

    by Min Kyung Chung, Bohyun Park, In Je Kim, Soo‐Kyung Cho, Dam Kim, Yoon‐Kyoung Sung, Chan‐Bum Choi, Jung‐Yoon Choe, Won Tae Chung, Seung‐Jae Hong, et al.

    Aim: Despite high clinical disease activity, some patients with active rheumatoid arthritis (RA) have normal acute phase reactant (APR) values. This study aimed to determine the clinical outcomes of active RA patients with normal APR values.Method: Of 5376 patients with RA enrolled in the Korean observational study network for arthritis (KORONA) registry, 400 patients with disease duration of 2.8 at baseline, biologic‐naïve, and erythrocyte sedimentation rate (ESR) and C‐reactive protein (CRP) drawn at both baseline and 2‐year follow‐up visits were identified. Patients were grouped according to baseline APR levels: normal APRs, one APR elevated, and both APRs elevated.Results: Baseline tender and swollen joint counts, mean CDAI and Health Assessment Questionnaire‐Disability Index (HAQ‐DI) scores were significantly lower in the normal APRs group compared with APR‐elevated groups (P < 0.0001). At 2‐year follow‐up, mean CDAI scores, HAQ‐DI, and percentage of the patient achieving remission were not significantly different between the normal APRs group compared with the APR‐elevated groups regardless of the baseline disease activity. However, in patients with baseline CDAI moderate to high disease activity, the normal APRs group less frequently required initiation of the biologic disease‐modifying anti‐rheumatic drugs compared with the APR‐elevated groups (P = 0.044).Conclusion: Active RA patients with normal APR values have milder disease presentation, but similar clinical outcomes to those with elevated APRs.


  • Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization

    by Soyoung Won, Soo-Kyung Cho, Dam Kim, Minkyung Han, Jiyoung Lee, Eun Jin Jang, Yoon-Kyoung Sung, Sang-Cheol Bae

    The objectives of this study are to identify the prevalence and incidence of rheumatoid arthritis (RA) and to investigate the patterns of medical care and drug utilization by RA patients in Korea. Korean National Health Insurance claims data were used for analysis. RA patients were defined as those having an RA code from 2009 to 2012 and using disease-modifying anti-rheumatic drugs (DMARDs) within 1 year after the code. RA patients identified in 2010 with a disease-free period for 12 months before the index date, and those who received continuous treatment in 2011–2013 were defined as incident cases. Patterns of medical care and drug utilization were compared among subgroups. The prevalence of RA increased yearly from 0.28% in 2009 to 0.32% in 2012. The incidence of RA in 2010 was 28.5 per 100,000 person-years. The use of biologic DMARDs (bDMARDs) increased from 2.31% in 2009 to 4.05% in 2012. Hydroxychloroquine (57.53–62.45%) was the most commonly used the conventional DMARDs, followed by methotrexate (49.99–51.87%). The use of bDMARDs (1.39 vs. 2.43%) was less frequent in EORA patients than YORA patients. Hydroxychloroquine (74.96 vs. 72.11%) was more frequently used, but methotrexate (55.24 vs. 59.25%) and sulfasalazine (27.96 vs. 32.72%) were used less frequently in EORA patients than in YORA patients. The prevalence of RA has increased in Korea. EORA patients used fewer bDMARDs, methotrexate, and sulfasalazine but more hydroxychloroquine than YORA patients.


  • Open Access

    New COX-2 Inhibitors

    by Dam Kim, Yoon-Kyoung Sung


  • Open Access

    Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis

    by Soo-Kyung Cho, Yoon-Kyoung Sung, Dam Kim, Soyoung Won, Chan-Bum Choi, Tae-Hwan Kim, Jae-Bum Jun, Dae-Hyun Yoo, Sang-Cheol Bae

    The concerns about the development of adverse events (AEs) in elderly RA patients as a result of age-related changes in drug metabolism and the presence of comorbid illnesses are emphasizing due to increasing prevalence of rheumatoid arthritis (RA) in old age. However, they tend to be inadequately represented in RA clinical trials because of the exclusion criteria that are commonly applied. The tolerability and safety of TNF inhibitors in elderly patients have not been also evaluated in clinical practice. This study aimed to evaluate the retention rate and safety of TNF inhibitors (TNFI) in elderly RA patients. Total 429 RA patients (838 person-years [PYs]) treated with TNFI from a retrospective biologic DMARDs registry. Patients were divided into an elderly (age ≥60 years) and a younger group (<60 years). The drug retention rates of both groups were compared using Kaplan-Meier curves. Potential predictors of TNFI discontinuation in the elderly were examined using Cox regression analysis. The incidence rate (IR) of serious adverse events (SAEs) in the elderly group was compared to that of the young group. Of the patients, 24.9 % (n = 107, 212 PYs) were in the elderly group. Regarding the retention rates of TNFI in 3 years, there was no significant difference between the elderly and younger group (p = 0.33). The major cause of discontinuation in elderly patients was AE (34.3 %), whereas that was drug ineffectiveness (41.7 %) in younger patients. Age (HR 1.09, CI 1.02-1.16) was a predictor of discontinuation, while the presence of comorbidity (HR 0.37, CI 0.15-0.91) had a protective effect against drug discontinuation in the elderly. The IR of SAEs in the elderly (6.13/100 PYs) was higher than in the younger group (5.11/100 PYs). The retention rate of TNFI in the elderly was comparable with that in younger patients. The major cause of discontinuation in the elderly patients was AEs, while it was drug ineffectiveness in younger patients. The IR of SAEs in the elderly was higher than in the younger patients.


  • Glucocorticoid acts differently on vertebral and hip fractures in Korean RA patients using National healthcare claims database

    by Dam Kim, Soo-Kyung Cho, Byeongju Park, Eun Jin Jang, Sang-Cheol Bae, Yoon-Kyoung Sung

    Background and objectives: Fracture in rheumatoid arthritis (RA) patient is more frequent than general population. One of the important reasons is use of glucocorticoid (GC) for treatment of RA. In this study, we aimed to identify the effect of GC on fracture of different site. Methods: Among RA patients ≧19 years, we established a retrospective cohort using Korean national healthcare claims database from Jan 2010 to Dec 2010, and then followed up until Dec 2013. RA patients who experienced fracture in year 2009 were excluded. Fractures were identified on the basis of selected ICD-10 codes and information about clinic visit until last visit. Information about oral GC use was collected until incidence of fracture or last visit. In multivariable logistic regression analysis, each of variables such as duration, mean dose, and highest daily dose of GC were adjusted for age, gender, payer type, type of institution, physician’s specialities, comorbidities and medication. Results: The 11 599 fractures in 9964 RA patients were observed among total of 138 240 RA patients. The 68% of patients used oral GC more than 3 months. Mean dose of GC was 6.1±4.7 mg and their highest daily dose was 16.20±15.8 mg. In adjusted analysis, duration of GC ≧6 months (OR 1.36, PPPPPP<0.03 in vertebral fracture) increased the risk of total and vertebral fracture. However, in hip fracture, neither duration nor dose of oral GC increased the risk. Conclusion: Use of oral GC increased the risk of total and vertebral fracture, however, it did not increase the risk of hip fracture in RA patients.

  • Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data

    by Hye-Lin Kim, Dam Kim, Eun Jin Jang, Min-Young Lee, Hyun Jin Song, Sun-Young Park, Soo-Kyung Cho, Yoon-Kyoung Sung, Chan-Bum Choi, Soyoung Won, et al.

    The aim of this study was to estimate the mapping model for EuroQol-5D (EQ-5D) utility values using the health assessment questionnaire disability index (HAQ-DI), pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) in a large, nationwide cohort of rheumatoid arthritis (RA) patients in Korea. The KORean Observational study Network for Arthritis (KORONA) registry data on 3557 patients with RA were used. Data were randomly divided into a modeling set (80 % of the data) and a validation set (20 % of the data). The ordinary least squares (OLS), Tobit, and two-part model methods were employed to construct a model to map to the EQ-5D index. Using a combination of HAQ-DI, pain VAS, and DAS28, four model versions were examined. To evaluate the predictive accuracy of the models, the root-mean-square error (RMSE) and mean absolute error (MAE) were calculated using the validation dataset. A model that included HAQ-DI, pain VAS, and DAS28 produced the highest adjusted R 2 as well as the lowest Akaike information criterion, RMSE, and MAE, regardless of the statistical methods used in modeling set. The mapping equation of the OLS method is given as EQ-5D = 0.95−0.21 × HAQ-DI−0.24 × pain VAS/100–0.01 × DAS28 (adjusted R 2 = 57.6 %, RMSE = 0.1654 and MAE = 0.1222). Also in the validation set, the RMSE and MAE were shown to be the smallest. The model with HAQ-DI, pain VAS, and DAS28 showed the best performance, and this mapping model enabled the estimation of an EQ-5D value for RA patients in whom utility values have not been measured.


  • Open Access

    Factors Contributing to Discordance between the 2011 ACR/EULAR Criteria and Physician Clinical Judgment for the Identification of Remission in Patients with Rheumatoid Arthritis

    by Yoon-Kyoung Sung, Soo-Kyung Cho, Dam Kim, Bo Young Yoon, Chan-Bum Choi, Hoon-Suk Cha, Jung-Yoon Choe, Won Tae Chung, Seung-Jae Hong, Jae-Bum Jun, et al.

    Sung YK, et al. J Korean Med Sci. 2016 Dec;31(12):1907-1913. https://doi.org/10.3346/jkms.2016.31.12.1907


  • Genetic association of CD247 (CD3ζ) with SLE in a large-scale multiethnic study

    by M Martins, A H Williams, M Comeau, M Marion, J T Ziegler, B I Freedman, J T Merrill, S B Glenn, J A Kelly, K M Sivils, et al.

    A classic T-cell phenotype in systemic lupus erythematosus (SLE) is the downregulation and replacement of the CD3ζ chain that alters T-cell receptor signaling. However, genetic associations with SLE in the human CD247 locus that encodes CD3ζ are not well established and require replication in independent cohorts. Our aim was therefore to examine, localize and validate CD247–SLE association in a large multiethnic population. We typed 44 contiguous CD247 single-nucleotide polymorphisms (SNPs) in 8922 SLE patients and 8077 controls from four ethnically distinct populations. The strongest associations were found in the Asian population (11 SNPs in intron 1, 4.99 × 10−4<P−2), where we further identified a five-marker haplotype (rs12141731–rs2949655–rs16859085–rs12144621–rs858554; G-G-A-G-A; Phap=2.12 × 10−5) that exceeded the most associated single SNP rs858554 (minor allele frequency in controls=13%; P=4.99 × 10−4, odds ratio=1.32) in significance. Imputation and subsequent association analysis showed evidence of association (PP-values (1.40 × 10−3<P−2), with one (rs704848) remaining significant after Bonferroni correction (Pmeta=2.66 × 10−2). Our study independently confirms and extends the association of SLE with CD247, which is shared by various autoimmune disorders and supports a common T-cell-mediated mechanism.


  • Open Access

    A Case of Lesch-Nyhan Syndrome Manifesting Only Chronic Gouty Arthritis without Neurologic Symptom

    by YooMi Yeo, Eun Young Choi, Hyae Jin Yoon, Sodam Jung, Dam Kim, Seunghun Lee, Kyung Bin Joo, Jae-Bum Jun

    Yeo Y, et al. J Rheum Dis. 2014 Aug;21(4):192-195. http://dx.doi.org/10.4078/jrd.2014.21.4.192